Skip Navigation

Skip Navigation

Issue No. 18  | April 24, 2009
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

New Tool: "What's New on AIDSinfo" Page Launched

AIDSinfo is proud to announce the launch of our new "What's New on AIDSinfo" page. This feature is accessible from the home page via a new button on the right above the Highlights and Features box.

"What's New" features updates to the AIDSinfo site that have occurred over the previous 30 days, including updates to guidelines, fact sheets, drug records, newsletters, press releases, home page highlights as well as any other changes to the site.


Study: Why Antibodies Fail to Control HIV

"Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the human immunodeficiency virus type 1 (HIV-1). The epitope for b12 maps to the CD4-binding site in the gp120 subunit of HIV-1's trimeric gp120-gp41 envelope spike, whereas 4E10 recognizes the membrane-proximal external region (MPER) of gp41....Increased distance and flexibility between antibody combining sites correlated with enhanced neutralization for both antibodies, suggesting restricted mobility for the trimeric spikes embedded in the virion surface. The size of a construct did not appear to be correlated with neutralization potency for b12, but larger 4E10 constructs exhibited a steric occlusion effect, which we interpret as evidence for restricted access to its gp41 epitope. The combination of limited avidity and steric occlusion suggests a mechanism for evading neutralization by antibodies that target epitopes in the highly conserved MPER of gp41."


ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228





previewPage